A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High Grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Conditions: Solid Cancer Interventions: Drug: R-DXd; Drug: Gemcitabine; Drug: Paclitaxel; Drug: Topotecan; Drug: PLD Sponsors: Daiichi Sankyo, Inc.; Merck Sharp& Dohme LLC Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials